These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 6342898)

  • 21. The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in the critically ill patient.
    Yogaratnam D; Miller MA; Smith BS
    Crit Care Nurs Clin North Am; 2005 Sep; 17(3):245-50. PubMed ID: 16115532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The past and the present of cardiac glycosides. III. Pharmacokinetics].
    Synek P
    Cas Lek Cesk; 1991 Feb; 130(5):148-51. PubMed ID: 2004406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of chronic cardiac insufficiency with cardiac glycosides].
    Bonelli J
    Wien Med Wochenschr; 1982 Oct; 132(19):442-9. PubMed ID: 7179995
    [No Abstract]   [Full Text] [Related]  

  • 24. [On the possible meproscillarin accumulation in patients with impaired renal function (author's transl)].
    Twittenhoff WD; Brittinger WD; Deckert DW; Belz GG; Schubert I
    Arzneimittelforschung; 1978; 28(3a):562-5. PubMed ID: 580591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of isoprazone, a new analgesic antipyretic agent, in the rat.
    Assandri A; Bernareggi A; Morrone A; Odasso G
    Farmaco Prat; 1984 Apr; 39(4):118-30. PubMed ID: 6610564
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug pharmacokinetics in the postoperative period.
    Elfstrom J
    Clin Pharmacokinet; 1979; 4(1):16-22. PubMed ID: 369764
    [No Abstract]   [Full Text] [Related]  

  • 27. [Toxic effects and pharmacokinetics of cardiac glycosides in mice with experimental radiation disease].
    Tilser I; Krupicková H; Kozák I
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1981; 24(1):123-41. PubMed ID: 6975978
    [No Abstract]   [Full Text] [Related]  

  • 28. Pulmonary disease and drug kinetics.
    du Souich P; McLean AJ; Lalka D; Erill S; Gibaldi M
    Clin Pharmacokinet; 1978; 3(4):257-66. PubMed ID: 354634
    [No Abstract]   [Full Text] [Related]  

  • 29. Digitalis therapy in renal failure with special regard to digitoxin.
    Vöhringer HF; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):175-84. PubMed ID: 7021432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of cardiac and renal disease on clinical pharmacokinetics].
    Soares Ade O
    Rev Port Cardiol; 1992 Feb; 11(2):185-90. PubMed ID: 1567640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of cefoperazone: a review.
    Craig WA; Gerber AU
    Drugs; 1981; 22 Suppl 1():35-45. PubMed ID: 6456890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical study of meproscillarin rates of inactivation and persistence, bioavailability and maintenance dose].
    Herken H; Brandes J
    Arzneimittelforschung; 1978; 28(3a):557-60. PubMed ID: 580590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biochemical principles of the development of new cardiac drugs of the digitalis type].
    Repke KR
    Pharmazie; 1972 Nov; 27(11):693-701. PubMed ID: 4265944
    [No Abstract]   [Full Text] [Related]  

  • 34. Proceedings: On the interaction of cardiac glycosides with the cardiac sarcolemma.
    Peters T; Preuner J
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R25. PubMed ID: 1143409
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinically relevant drug interactions with cardiac glycosides].
    Bodem G
    Fortschr Med; 1982 Oct; 100(38):1739-42. PubMed ID: 7141372
    [No Abstract]   [Full Text] [Related]  

  • 36. Relationship between pharmacokinetics and bioavailability of cefroxadine (CGP 9000) and renal function.
    Bergan T; Brodwall EK; Larsen EW
    Chemotherapy; 1983; 29(3):163-73. PubMed ID: 6872614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [On the pharmacokinetics of peruvoside. I. Comparative clinical and experimental animal studies].
    Hundeshagen H; Zeidler U; Fabel H; Garbe A; Nowak H
    Arzneimittelforschung; 1968 Dec; 18(12):1592-6. PubMed ID: 5756259
    [No Abstract]   [Full Text] [Related]  

  • 38. Serum concentration monitoring of cardiac glycosides. How helpful is it for adjusting dosage regimens?
    Dobbs RJ; O'Neill CJ; Deshmukh AA; Nicholson PW; Dobbs SM
    Clin Pharmacokinet; 1991 Mar; 20(3):175-93. PubMed ID: 2025980
    [No Abstract]   [Full Text] [Related]  

  • 39. [Recent acquisitions in the study of the pharmacology of cardiac glycosides. Pharmacokinetic approach to therapy with cardiac glycosides].
    Lesne M
    J Pharm Belg; 1973; 28(2):217-33. PubMed ID: 4733470
    [No Abstract]   [Full Text] [Related]  

  • 40. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.
    Säwe J
    Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.